Takeda is organized around five core businesses: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for over 80% of revenue. It also has a developing ...

Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes During Maintenance Therapy of Vedolizumab in Crohn's Disease (Tu1876) Real World Evidence of Serum Adalimumab Clearance and ...

Japanese drugmaker Takeda (TYO: 4502) posted revenue of 4.58 trillion yen ($31.7 billion) for the fiscal year ended March 31, ...

Given the dramatic changes in GLP-1 and biologic treatments and their rapid adoption, real-world data illuminating patient feedback and prescriber rationale is essential.” — Chris Baker, Amplity CEO ...

Nine presentations on Inflammatory Bowel Disease Prediction, Monitoring and Therapy Optimization SAN DIEGO, CA / ACCESS Newswire / May 4, 2025 / Prometheus Laboratories Inc. ("Prometheus"), a leader i ...

AVT16 is a human monoclonal antibody and a biosimilar candidate to Entyvio® (vedolizumab). Vedolizumab targets and binds ...

The updated results show SPY001 continues to be well tolerated, has a half-life more than three times longer than vedolizumab based on pharmacokinetic (PK) modeling, and maintains sustained target ...

Those have been sort of our most longstanding therapies for Crohn's. We've also had vedolizumab for a number of years for Crohn's disease. While we've had stelara for Crohn's, more recently ...

Vedolizumab (Entyvio) and IBD Biologics. Although Immunic’s GI focus is currently on celiac, we think it is worthwhile to compare IMU‑856 to existing IBD drugs. Vedolizumab (Takeda’s Entyvio ...

Johnson & Johnson announces new data from Tremfya phase 3 QUASAR LTE study in adults with moderately-to-severely active ulcerative colitis ...